Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8969116 | 0.98 | RAB9A (0.39) | RAB9ATAAR1ACECTSVCTSL | |
| SCHEMBL8969288 | 0.98 | RAB9A (0.39) | RAB9ATAAR1ACECTSVCTSL | |
| SCHEMBL8970403 | 0.96 | RAB9A (0.40) | RAB9ATAAR1ACECTSVCTSL | |
| SCHEMBL1270288 | 0.86 | PEPD (0.36) | TAAR1ACEPEPDALDH1A1 | |
| SCHEMBL26725054 | 0.86 | TSHR (0.36) | RAB9ACTSVCTSLCTSBCTSS | |
| SCHEMBL8970583 | 0.82 | GPR88 (0.36) | TAAR1 | |
| SCHEMBL26725056 | 0.82 | TSHR (0.36) | RAB9ACTSVCTSLCTSBCTSS | |
| SCHEMBL8970288 | 0.81 | GPR88 (0.37) | TAAR1 | |
| SCHEMBL8969008 | 0.81 | GPR88 (0.37) | TAAR1 | |
| SCHEMBL8163124 | 0.79 | ALDH1A1 (0.38) | PEPDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-0376294-B1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI LTD (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5370821-A | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5269965-A | Optically active compounds, liquid crystal compositions comprising said compounds and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0376294-A1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI, LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
| US-4347379-A | REACTING AN ALCOHOL OF THIOL, A HALOFORM, ALKALI METAL HYDROXIDE, AND PHASE TRANSFER AGENT | THE B. F. GOODRICH COMPANY (US) | 1982-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | RAB9A 2346/4885TAAR1 1987/4885ACE 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.